Boostagen (tetanus toxoid, reduced diphtheria toxoid and recombinant acellular pertussis vaccine, recombinant TdaP) / BioNet Asia - LARVOL DELTA

Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines. (PubMed, Vaccine) - "BioNet licensed (TdaP5 and Tdap2) and candidate vaccines (Tdap1 and ap1) when given to pregnant women in the second or third trimester of gestation are safe and have induced passive pertussis immunity to infants."

Journal • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus

WoMANPOWER: Maternal Pertussis Wholecell Responses (clinicaltrials.gov) - P2 | N=181 | Completed | Sponsor: St George's, University of London | Recruiting ➔ Completed | Trial completion date: Dec 2021 ➔ Jun 2023 | Trial primary completion date: Sep 2021 ➔ Jun 2023

Trial completion • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • Pertussis • Respiratory Diseases

A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women. (PubMed, Vaccine) - "Vaccine formulations containing PT were safe and immunogenic in pregnant women. The ap1 vaccine, with the lowest cost and reactogenicity, may be suitable for use in pregnant women when diphtheria and tetanus toxoids are not needed. This study is registered in the Thai Clinical Trial Registry (www."

Journal • P2 data • Infectious Disease • Novel Coronavirus Disease • Pertussis • Respiratory Diseases • Tetanus

5-year Follow-up After a Single Dose Acellular Pertussis Vaccination (clinicaltrials.gov) - P=N/A; N=159; Completed; Sponsor: Mahidol University; Enrolling by invitation ➔ Completed

Trial completion • Infectious Disease • Pertussis • Respiratory Diseases

A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age. (PubMed, Vaccine) - "All recombinant acellular pertussis vaccines were safe and immunogenic in women of childbearing age, and all met pre-defined immunogenicity criteria to advance to a trial in pregnant women."

Clinical • Journal • P2 data • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus

[VIRTUAL] RECOMBINANT ACELLULAR PERTUSSIS VACCINATION DURING PREGNANCY INDUCES HIGH CORD BLOOD PERTUSSIS ANTIBODIES (ESPID 2021) - "Clinical Trial Registration: Thai Clinical Trial Registry TCTR20200528006 Background: Two genetically inactivated acellular pertussis vaccines, a recombinant pertussis-only vaccine (Pertagen®, aPgen) and the combined formulation containing aPgen, tetanus and reduced diphtheria toxoids (Boostagen®, TdaPgen) are licensed in Thailand for booster pertussis immunisation in individuals aged 11 years and older, including pregnant women. Maternal vaccination with genetically-detoxified Pertussis Toxin (PTgen) containing recombinant pertussis vaccines may provide long-lasting protection against severe pertussis in young infants. In addition, the availability of monovalent aPgen vaccine provides an alternative to Tdap vaccines for maternal pertussis immunization when Td vaccination in pregnant women is not needed."

Infectious Disease • Pertussis • Respiratory Diseases • Tetanus